On July 8, Akeso rose 3.12% in regular trading, trading at 99.75 HKD/share, with turnover of HKD 205 million. The stock rebounded following a 3.24% decline in the prior session when the broader biotech sector weakened.

On the news front, innovative drug payment reform continues to provide policy catalysts. All indications of Akeso's five self-developed new drugs have been included in China's national medical insurance program, and the company's new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. The broader policy backdrop includes the National Healthcare Security Administration's advancement of the dual medical insurance and commercial insurance directory negotiation process, alongside new mechanisms such as pre-declaration and 8-year price protection, providing a more stable policy outlook for innovative drug commercialization.

Within the Biotechnology sector, individual stocks showed mixed performance: SKB BIO down 5.18%, Remegen up 3.24%, Innovent Bio up 1.89%, BeiGene up 1.68%, Keymed Bio-B up 0.35%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)